Aflibercept

Indication

Treating choroidal neovascularisation (NICE TA486)

NICE TA486 - Aflibercept for treating choroidal neovascularisation

Red

Brand:

Eylea®

Nice TA:

486

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Eye

Background

Aflibercept is recommended, within its marketing authorisation, as an option for treating visual impairment because of myopic choroidal neovascularisation in adults, only if the company provides aflibercept with the discount agreed in the patient access scheme.

If patients and their clinicians consider both aflibercept and ranibizumab to be suitable treatments, the least costly should be used, taking into account anticipated administration costs, dosage and price per dose.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 01 - Dec - 2017